SCHEDULE: Kallman Trust Discloses 9.99% Stake in DarioHealth

Craig Kallman 2015 Living Trust and Craig Kallman report a 9.99% passive beneficial ownership in DarioHealth Corp. common stock.

Summary

• Craig Kallman 2015 Living Trust and Craig Kallman (collectively, "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in DarioHealth Corp.
• The Reporting Persons beneficially own an aggregate of 675,165 shares of DarioHealth Corp. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• The beneficial ownership includes 604,803 shares of common stock directly held and a portion of pre-funded warrants, with the total beneficial ownership capped at 9.99% due to contractual restrictions on the warrants.
• The percentage ownership is calculated based on 6,758,412 common shares outstanding as of the filing date.
• All share figures presented reflect a 1-for-20 reverse stock split effected by DarioHealth Corp. on August 28, 2025.
• The Reporting Persons have shared voting and shared dispositive power over all 675,165 beneficially owned shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of ownership and is generally neutral in sentiment. The disclosure of a significant stake by an investor can be seen as a minor positive, but the filing itself does not contain performance or operational news.

Positives

• A significant passive stake (9.99%) by an individual and associated trust can be viewed as a vote of confidence in the company's long-term prospects by a notable investor.

Negatives

• None explicitly mentioned in this ownership disclosure.

Risks

• None explicitly mentioned in this ownership disclosure.

Future Outlook

The filing is an ownership disclosure and does not contain forward-looking statements or guidance from the company.

Industry Context

This filing indicates a significant passive investment by Craig Kallman and his trust in DarioHealth Corp., a digital therapeutics company. Such disclosures are common for institutional investors accumulating stakes, but this filing does not provide broader industry context or competitive analysis.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain information for comparison to industry-specific operational or financial benchmarks. It simply reports a significant stake by an individual and associated trust.

Legal Proceedings

• None mentioned in this ownership disclosure.

Related Party Transactions

• None mentioned in this ownership disclosure.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an individual and associated trust may be viewed positively as a vote of confidence, potentially increasing investor interest.
• Company Management: Awareness of a significant passive shareholder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Next Steps

• The filing does not mention any specific future actions, events, or milestones by the company or the reporting persons, beyond the regulatory requirement for future amendments if ownership changes significantly.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a regulatory disclosure of a significant passive ownership stake by Craig Kallman and his trust in DarioHealth Corp. While the presence of a notable investor holding a 9.99% stake could be interpreted as a positive signal of confidence, the filing itself does not provide new financial performance data, strategic updates, or operational insights that would warrant a change in investment recommendation. It confirms an existing significant position, which typically supports a 'hold' stance for investors awaiting further fundamental news.

Keywords

DarioHealth Corp, DRX, Craig Kallman, Schedule 13G, beneficial ownership, common stock, warrants, institutional investor, reverse stock split